Trends in United States prostate cancer incidence rates by age and stage, 1995-2012

Richard M. Hoffman, Angela L.W. Meisner, Wadih Arap, Marc Barry, Satyan K. Shah, Steven B. Zeliadt, Charles L. Wiggins

Research output: Contribution to journalReview article

19 Citations (Scopus)

Abstract

Background: The advent of PSA testing in the late 1980s substantially increased prostate cancer incidence rates. Concerns about overscreening and overdiagnosis subsequently led professional guidelines (circa 2000 and later) to recommend against routine PSA testing. We evaluated trends in prostate cancer incidence, including late-stage diagnoses, from 1995 through 2012. Methods: We used joinpoint regression analyses to evaluate all-, localized/regional-, and distant-stage prostate cancer incidence trends based on Surveillance, Epidemiology, and End Results (SEER) data. We stratified analyses by age (50-69, 70). We reported incidence trends as annual percent change (APC). Results: Overall age-adjusted incidence rates for localized/ regional stage prostate cancer have been declining since 2001, sharply from 2010 to 2012 [APC, -13.1; 95% confidence intervals (CI), -23.5 to -1.3]. Distant-stage incidence rates have declined since 1995, with greater declines from 1995 to 1997 (APC, -8.4; 95% CI, 2.3 to -14.1) than from 2003 to 2012 (APC, -1.0; 95% CI, -1.7 to -0.4). Distant-stage incidence rates declined for men ages 70 from 1995 to 2012, but increased in men ages 50 to 69 years from 2004 to 2012 (APC, 1.7; 95% CI, 0.2 to 3.2). Conclusions: Guidelines discouraging routine prostate cancer screening were temporally associated with declining localized/ regional prostate cancer incidence rates; however, incidence rates of distant-stage disease are now increasing in younger men. Impact: This trend may adversely affect prostate cancer mortality rates.

Original languageEnglish (US)
Pages (from-to)259-263
Number of pages5
JournalCancer Epidemiology Biomarkers and Prevention
Volume25
Issue number2
DOIs
StatePublished - Feb 1 2016

Fingerprint

Prostatic Neoplasms
Incidence
Confidence Intervals
Guidelines
Delayed Diagnosis
Early Detection of Cancer
Epidemiology
Regression Analysis
Mortality

All Science Journal Classification (ASJC) codes

  • Epidemiology
  • Oncology

Cite this

Hoffman, Richard M. ; Meisner, Angela L.W. ; Arap, Wadih ; Barry, Marc ; Shah, Satyan K. ; Zeliadt, Steven B. ; Wiggins, Charles L. / Trends in United States prostate cancer incidence rates by age and stage, 1995-2012. In: Cancer Epidemiology Biomarkers and Prevention. 2016 ; Vol. 25, No. 2. pp. 259-263.
@article{48844e3fac804c3a9ba4c7e15e440948,
title = "Trends in United States prostate cancer incidence rates by age and stage, 1995-2012",
abstract = "Background: The advent of PSA testing in the late 1980s substantially increased prostate cancer incidence rates. Concerns about overscreening and overdiagnosis subsequently led professional guidelines (circa 2000 and later) to recommend against routine PSA testing. We evaluated trends in prostate cancer incidence, including late-stage diagnoses, from 1995 through 2012. Methods: We used joinpoint regression analyses to evaluate all-, localized/regional-, and distant-stage prostate cancer incidence trends based on Surveillance, Epidemiology, and End Results (SEER) data. We stratified analyses by age (50-69, 70). We reported incidence trends as annual percent change (APC). Results: Overall age-adjusted incidence rates for localized/ regional stage prostate cancer have been declining since 2001, sharply from 2010 to 2012 [APC, -13.1; 95{\%} confidence intervals (CI), -23.5 to -1.3]. Distant-stage incidence rates have declined since 1995, with greater declines from 1995 to 1997 (APC, -8.4; 95{\%} CI, 2.3 to -14.1) than from 2003 to 2012 (APC, -1.0; 95{\%} CI, -1.7 to -0.4). Distant-stage incidence rates declined for men ages 70 from 1995 to 2012, but increased in men ages 50 to 69 years from 2004 to 2012 (APC, 1.7; 95{\%} CI, 0.2 to 3.2). Conclusions: Guidelines discouraging routine prostate cancer screening were temporally associated with declining localized/ regional prostate cancer incidence rates; however, incidence rates of distant-stage disease are now increasing in younger men. Impact: This trend may adversely affect prostate cancer mortality rates.",
author = "Hoffman, {Richard M.} and Meisner, {Angela L.W.} and Wadih Arap and Marc Barry and Shah, {Satyan K.} and Zeliadt, {Steven B.} and Wiggins, {Charles L.}",
year = "2016",
month = "2",
day = "1",
doi = "10.1158/1055-9965.EPI-15-0723",
language = "English (US)",
volume = "25",
pages = "259--263",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

Trends in United States prostate cancer incidence rates by age and stage, 1995-2012. / Hoffman, Richard M.; Meisner, Angela L.W.; Arap, Wadih; Barry, Marc; Shah, Satyan K.; Zeliadt, Steven B.; Wiggins, Charles L.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 25, No. 2, 01.02.2016, p. 259-263.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Trends in United States prostate cancer incidence rates by age and stage, 1995-2012

AU - Hoffman, Richard M.

AU - Meisner, Angela L.W.

AU - Arap, Wadih

AU - Barry, Marc

AU - Shah, Satyan K.

AU - Zeliadt, Steven B.

AU - Wiggins, Charles L.

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Background: The advent of PSA testing in the late 1980s substantially increased prostate cancer incidence rates. Concerns about overscreening and overdiagnosis subsequently led professional guidelines (circa 2000 and later) to recommend against routine PSA testing. We evaluated trends in prostate cancer incidence, including late-stage diagnoses, from 1995 through 2012. Methods: We used joinpoint regression analyses to evaluate all-, localized/regional-, and distant-stage prostate cancer incidence trends based on Surveillance, Epidemiology, and End Results (SEER) data. We stratified analyses by age (50-69, 70). We reported incidence trends as annual percent change (APC). Results: Overall age-adjusted incidence rates for localized/ regional stage prostate cancer have been declining since 2001, sharply from 2010 to 2012 [APC, -13.1; 95% confidence intervals (CI), -23.5 to -1.3]. Distant-stage incidence rates have declined since 1995, with greater declines from 1995 to 1997 (APC, -8.4; 95% CI, 2.3 to -14.1) than from 2003 to 2012 (APC, -1.0; 95% CI, -1.7 to -0.4). Distant-stage incidence rates declined for men ages 70 from 1995 to 2012, but increased in men ages 50 to 69 years from 2004 to 2012 (APC, 1.7; 95% CI, 0.2 to 3.2). Conclusions: Guidelines discouraging routine prostate cancer screening were temporally associated with declining localized/ regional prostate cancer incidence rates; however, incidence rates of distant-stage disease are now increasing in younger men. Impact: This trend may adversely affect prostate cancer mortality rates.

AB - Background: The advent of PSA testing in the late 1980s substantially increased prostate cancer incidence rates. Concerns about overscreening and overdiagnosis subsequently led professional guidelines (circa 2000 and later) to recommend against routine PSA testing. We evaluated trends in prostate cancer incidence, including late-stage diagnoses, from 1995 through 2012. Methods: We used joinpoint regression analyses to evaluate all-, localized/regional-, and distant-stage prostate cancer incidence trends based on Surveillance, Epidemiology, and End Results (SEER) data. We stratified analyses by age (50-69, 70). We reported incidence trends as annual percent change (APC). Results: Overall age-adjusted incidence rates for localized/ regional stage prostate cancer have been declining since 2001, sharply from 2010 to 2012 [APC, -13.1; 95% confidence intervals (CI), -23.5 to -1.3]. Distant-stage incidence rates have declined since 1995, with greater declines from 1995 to 1997 (APC, -8.4; 95% CI, 2.3 to -14.1) than from 2003 to 2012 (APC, -1.0; 95% CI, -1.7 to -0.4). Distant-stage incidence rates declined for men ages 70 from 1995 to 2012, but increased in men ages 50 to 69 years from 2004 to 2012 (APC, 1.7; 95% CI, 0.2 to 3.2). Conclusions: Guidelines discouraging routine prostate cancer screening were temporally associated with declining localized/ regional prostate cancer incidence rates; however, incidence rates of distant-stage disease are now increasing in younger men. Impact: This trend may adversely affect prostate cancer mortality rates.

UR - http://www.scopus.com/inward/record.url?scp=84957794710&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957794710&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-15-0723

DO - 10.1158/1055-9965.EPI-15-0723

M3 - Review article

VL - 25

SP - 259

EP - 263

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 2

ER -